Since IFNγ exposure of cancer cells induces PD-L1 production, mutations in IFNγ signaling components JAK1 and JAK2 would lead to clonal evolution of PD-L1-negative tumor cells, which are not responsive to anti-PD-1 treatment (149). Here, IFNG is linked to neoplasm.